Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.71+0.10 (+0.26%)
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Roivant Sciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Roivant Sciences's total debt was $12.00M at Jun 30, 2024. For fiscal 2023 it was $12.00M, down 70.5% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Mar 31, 2024 | $12.00M | -70.5% |
| FY2022 | Mar 31, 2023 | $40.72M | -80.6% |
| FY2021 | Mar 31, 2022 | $210.03M | +23.3% |
| FY2020 | Mar 31, 2021 | $170.28M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | $12.00M | -73.0% |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | $12.00M | -70.5% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $45.71M | +21.2% |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | $49.00M | +37.0% |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | $44.41M | +33.3% |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $40.72M | -80.6% |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | $37.72M | -81.5% |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | $35.75M | -82.1% |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | $33.30M | -82.1% |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | $210.03M | +23.3% |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | $204.04M | – |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | $199.87M | – |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | $186.35M | – |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | $170.28M | – |
See a number that looks wrong?